INREBIC DIN 02502445
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Molecule: FEDRATINIB (FEDRATINIB HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | FEDRATINIB (FEDRATINIB HYDROCHLORIDE) 100 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EJ02 FEDRATINIB |
| Original market date | 20-May-2021 |
| Current status date | 03-Feb-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32170 | 2023-11-23 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 23965 | 2020-07-27 | New Drug Submission (NDS) |